Menu Close
Close
Make an Appointment

Clinical Trials & Research

  • Priyanka Jujuvarapu, Shilpa Gupta, Vijay Dalal. Primary extranodal classical Hodgkin lymphoma presenting as a chest wall mass mimicking tuberculosis: A rare case report with long-term Follow-up
  • Gupta S. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series. Leukemia & Lymphoma, 2012.
  • Book Chapter: Gastrointestinal Lymphomas in Recent Advances in Surgery – 2012, Jaypee
  • Principal Investigator / Co-Investigator in multiple trials, including:
  • 2024 | Phase III | Observational study on anticoagulant prescribing patterns – Principal Investigator.
  • 2023 | Phase III | PZN-128 in Chronic ITP – Principal Investigator.
  • Earlier experience: Multiple Phase III trials in colorectal cancer, breast cancer, T-cell lymphoma, ovarian cancer, and pancreatic cancer (2015–2017).
  • Dr. Shilpa Gupta, PI, A multicenter, randomised, open-label, three-parallel groups, phase 2-study to evaluate the efficacy and safety of masitinib with dexamethasone,gemcitabine with dexamethasone and the combination of masitinib,gemcitabine and dexamethasone in patients with relapsed or refractoryperipheral T-cell lymphoma, Trials, 27-Jun-16, NA, National, PhaseII/III, Completed.
  • Dr. Shilpa Gupta, Co-I, A multicenter, open label, randomized, balanced, two treatment, two period, two sequence, two way crossover, single dose, bioequivalence study of Doxorubicin Hydrochloride Liposome Injection (20mg/10mL) of Mylan Laboratories Limited, India with Doxorubicin Hydrochloride Liposome Injection for intravenous infusion 20 mg/10 mL. Manufactured By: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, administered in female patients with ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy under fed condition., Trials, 19-Jun-17, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, Co-I, A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib, and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), Trials, 11-Jun-18, NA, International, III, Completed.
  • Dr. Shilpa Gupta, Co-I, Randomized, Assessor-Blind, Multicentre, Parallel Group, Two Arms, Clinical Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Rituximab (Test Product, Zydus) in comparison with Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL)”. (Trial No. RITU.17.001)., Trials, 8-Sep-18, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, Co-I, A Prospective, Randomized, Multicenter, Comparative, Open-label, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-TrastuzumabEmtansine (ZRC3256;Cadila Healthcare Ltd) and Reference-TrastuzumabEmtansine(Kadcyla; Roche Products (India) Pvt. Ltd.) in HER2- Positive Metastatic Breast Cancer Patients”. (Trial No. TDM11.17.001)., Trials, 8- Sep-18, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, PI, A randomized, international, multicenter single-blind study to compare the efficacy and safety of PZN-128 powder for solution for subcutaneous injection 250 μg (PharmasyntezNord JSC, Russia) versus comparator drug in patients with chronic idiopathic (immune) thrombocytopenic purpura, Trials, 19-Dec-23, REF/2023/09/03786, International, III, Completed.
  • Dr. Shilpa Gupta, PI, A single center, prospective, observational study to evaluate the factorsinfluencing the prescription choices of anticoagulants and to assess the outcomes in patients prescribed these specific anticoagulants., Investigator Initiated, 17-Sep-24, CTRI/2024/10/074833, Hospital Based, NA, Completed.